Healthpeak Properties (DOC) recently reported better than expected first quarter 2026 results, raised full year earnings guidance and completed the Janus Living IPO, moves that appear central to the latest stock reaction.

The stock’s recent move appears to reflect a reset in sentiment, with a 7 day share price return of 21.58% and year to date share price return of 21.36%, while the 5 year total shareholder return of a 21.10% decline shows that longer term momentum has been weaker.

If recent earnings surprises have you looking beyond a single stock, this is a useful moment to broaden your search and check out 18 top founder-led companies

With the share price now just below the average analyst target and an estimated intrinsic value implying a larger discount, the key question is whether Healthpeak still trades below its fundamentals or if the market is already pricing in future growth.

Most Popular Narrative: 2.5% Undervalued

Healthpeak Properties last closed at $19.66, compared with an estimated fair value of about $20.17, so the popular narrative still sees modest upside from here.

Ongoing, multi-year demographic tailwinds from an aging U.S. population are increasing demand for senior housing and independent living facilities (like Healthpeak's CCRC portfolio). This supports higher occupancy and growing entrance fees, which directly contribute to revenue and operating earnings growth.

Want to see what is really driving that fair value gap? The narrative leans heavily on steady revenue, firmer margins, and a future profit multiple that stands out. The exact mix of growth, profitability and required return is already mapped out, but the key assumptions sit beneath the headline number.

Result: Fair Value of $20.17 (UNDERVALUED)

However, this depends on lab tenant health and refinancing conditions, as biotech credit stress or tougher capital markets could quickly weaken earnings and pressure the current thesis.

Another Way To Look At Valuation

The story shifts when you switch from fair value estimates to the P/E ratio. Healthpeak trades on a P/E of 61.7x, compared with 24.2x for the global Health Care REITs group and a fair ratio of 30.9x, which points to a much richer pricing profile and less room for error.

For a cleaner sense check, compare that current multiple to what the numbers suggest it could gravitate toward over time, and decide whether you are comfortable paying this kind of premium for earnings that analysts expect to decline over the next few years. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, this is a good time to review the numbers, consider both perspectives, and decide where you stand on Healthpeak’s risk reward balance with 1 key reward and 4 important warning signs

Ready for more investment ideas?

If Healthpeak has sharpened your focus on valuation and risk, do not stop here. Use curated stock ideas to pressure test and strengthen your wider portfolio decisions.

• Target potential mispricings across the market by scanning 51 high quality undervalued stocks and see which stocks currently align with your return and quality expectations.
• Strengthen the income side of your portfolio by reviewing 12 dividend fortresses built around higher yielding companies with robust profiles.
• Lower overall portfolio risk by shortlisting companies from the 72 resilient stocks with low risk scores that score well on resilience and balance sheet quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.